Evaluation of the Diagnostic Stability of the Early Autism Spectrum Disorder Phenotype in the General Population Starting at 12 Months.


Journal

JAMA pediatrics
ISSN: 2168-6211
Titre abrégé: JAMA Pediatr
Pays: United States
ID NLM: 101589544

Informations de publication

Date de publication:
01 06 2019
Historique:
pubmed: 30 4 2019
medline: 25 2 2020
entrez: 30 4 2019
Statut: ppublish

Résumé

Universal early screening for autism spectrum disorder (ASD) in primary care is becoming increasingly common and is believed to be a pivotal step toward early treatment. However, the diagnostic stability of ASD in large cohorts from the general population, particularly in those younger than 18 months, is unknown. Changes in the phenotypic expression of ASD across early development compared with toddlers with other delays are also unknown. To examine the diagnostic stability of ASD in a large cohort of toddlers starting at 12 months of age and to compare this stability with that of toddlers with other disorders, such as developmental delay. In this prospective cohort study performed from January 1, 2006, to December 31, 2018, a total of 2241 toddlers were referred from the general population through a universal screening program in primary care or community referral. Eligible toddlers received their first diagnostic evaluation between 12 and 36 months of age and had at least 1 subsequent evaluation. Diagnosis was denoted after each evaluation visit as ASD, ASD features, language delay, developmental delay, other developmental issue, typical sibling of an ASD proband, or typical development. Diagnostic stability coefficients were calculated within 2-month age bands, and logistic regression models were used to explore the associations of sex, age, diagnosis at first visit, and interval between first and last diagnosis with stability. Toddlers with a non-ASD diagnosis at their first visit diagnosed with ASD at their last were designated as having late-identified ASD. Among the 1269 toddlers included in the study (918 [72.3%] male; median age at first evaluation, 17.6 months [interquartile range, 14.0-24.4 months]; median age at final evaluation, 36.2 months [interquartile range, 33.4-40.9 months]), the overall diagnostic stability for ASD was 0.84 (95% CI, 0.80-0.87), which was higher than any other diagnostic group. Only 7 toddlers (1.8%) initially considered to have ASD transitioned into a final diagnosis of typical development. Diagnostic stability of ASD within the youngest age band (12-13 months) was lowest at 0.50 (95% CI, 0.32-0.69) but increased to 0.79 by 14 months and 0.83 by 16 months (age bands of 12 vs 14 and 16 months; odds ratio, 4.25; 95% CI, 1.59-11.74). A total of 105 toddlers (23.8%) were not designated as having ASD at their first visit but were identified at a later visit. The findings suggest that an ASD diagnosis becomes stable starting at 14 months of age and overall is more stable than other diagnostic categories, including language or developmental delay. After a toddler is identified as having ASD, there may be a low chance that he or she will test within typical levels at 3 years of age. This finding opens the opportunity to test the impact of very early-age treatment of ASD.

Identifiants

pubmed: 31034004
pii: 2732144
doi: 10.1001/jamapediatrics.2019.0624
pmc: PMC6547081
doi:

Types de publication

Clinical Trial Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

578-587

Subventions

Organisme : NIMH NIH HHS
ID : R01 MH110558
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH104446
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH036840
Pays : United States
Organisme : NIMH NIH HHS
ID : P50 MH081755
Pays : United States
Organisme : NIDCD NIH HHS
ID : R01 DC016385
Pays : United States

Commentaires et corrections

Type : ErratumIn

Références

Eur J Neurosci. 2018 Mar;47(6):497-514
pubmed: 28922520
J Autism Dev Disord. 2014 Dec;44(12):2981-95
pubmed: 25212413
Pediatrics. 2013 Apr;131(4):e1121-7
pubmed: 23530174
Pediatrics. 2010 Jan;125(1):e17-23
pubmed: 19948568
Autism Res Treat. 2015;2015:386951
pubmed: 25648749
Monogr Soc Res Child Dev. 1994;59(5):1-173; discussion 174-85
pubmed: 7845413
Nat Rev Neurosci. 2000 Dec;1(3):191-8
pubmed: 11257907
Autism. 2019 Apr;23(3):653-664
pubmed: 29633852
Pediatrics. 2007 Nov;120(5):1183-215
pubmed: 17967920
MMWR Surveill Summ. 2018 Apr 27;67(6):1-23
pubmed: 29701730
J Speech Lang Hear Res. 2003 Jun;46(3):544-60
pubmed: 14696985
Audiol Neurootol. 2016;21(2):113-26
pubmed: 27074000
Res Dev Disabil. 2014 Dec;35(12):3632-44
pubmed: 25241118
J Pediatr. 2016 Sep;176:182-94
pubmed: 27421956
Child Dev. 2011 Jul-Aug;82(4):1199-209
pubmed: 21545581
J Autism Dev Disord. 2018 Jul;48(7):2368-2378
pubmed: 29453706
Brain Res. 1979 Mar 16;163(2):195-205
pubmed: 427544
Autism. 2008 Sep;12(5):487-511
pubmed: 18805944
Audiol Neurootol. 2004 Jul-Aug;9(4):224-33
pubmed: 15205550
Dev Psychopathol. 2018 May;30(2):553-569
pubmed: 28803559
J Child Psychol Psychiatry. 2015 Sep;56(9):988-98
pubmed: 25921776
Mol Psychiatry. 2012 Dec;17(12):1174-9
pubmed: 22869033
Dev Med Child Neurol. 2016 Apr;58(4):369-75
pubmed: 26303216
JAMA. 2016 Feb 16;315(7):691-6
pubmed: 26881372
Mol Psychiatry. 2019 Jan;24(1):88-107
pubmed: 29934544
J Pediatr. 2011 Sep;159(3):458-465.e1-6
pubmed: 21524759
Pediatrics. 2014 Jan;133(1):37-45
pubmed: 24366990
J Autism Dev Disord. 2009 Sep;39(9):1305-20
pubmed: 19415479
J Child Psychol Psychiatry. 2013 Jul;54(7):763-71
pubmed: 23227853
Nat Rev Neurosci. 2006 Sep;7(9):697-709
pubmed: 16924259
Autism Res. 2016 Jul;9(7):790-800
pubmed: 26613202
Pediatrics. 2013 Sep;132(3):e735-46
pubmed: 23958771
J Dev Behav Pediatr. 2015 Sep;36(7):536-43
pubmed: 26348972
J Child Psychol Psychiatry. 2014 May;55(5):485-94
pubmed: 24313878
J Am Acad Child Adolesc Psychiatry. 2015 Jul;54(7):580-7
pubmed: 26088663
J Pediatr. 2017 Apr;183:141-146.e1
pubmed: 28162768
Pediatrics. 2004 Apr;113(4):846-57
pubmed: 15060237
Autism. 2013 Sep;17(5):527-40
pubmed: 22781058
Biol Psychiatry. 2016 Jul 15;80(2):120-128
pubmed: 26707088

Auteurs

Karen Pierce (K)

Department of Neurosciences, University of California, San Diego, La Jolla.

Vahid H Gazestani (VH)

Department of Neurosciences, University of California, San Diego, La Jolla.
Department of Pediatrics, University of California, San Diego, La Jolla.

Elizabeth Bacon (E)

Department of Neurosciences, University of California, San Diego, La Jolla.

Cynthia Carter Barnes (CC)

Department of Neurosciences, University of California, San Diego, La Jolla.

Debra Cha (D)

Department of Neurosciences, University of California, San Diego, La Jolla.

Srinivasa Nalabolu (S)

Department of Neurosciences, University of California, San Diego, La Jolla.

Linda Lopez (L)

Department of Neurosciences, University of California, San Diego, La Jolla.

Adrienne Moore (A)

Department of Neurosciences, University of California, San Diego, La Jolla.

Sunny Pence-Stophaeros (S)

Department of Neurosciences, University of California, San Diego, La Jolla.

Eric Courchesne (E)

Department of Neurosciences, University of California, San Diego, La Jolla.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH